Sep 26, 2007 by Brian LawlerFollowing the Fallen Biotech Class of 2006Ever wondered what happened to last year's biotech disaster stories?
Sep 25, 2007 by Brian LawlerAmgen's European AdventuresA conditional and limited approval of its cancer drug points to good news in a year of disappointments.
Sep 25, 2007 by Brian LawlerAcorda at a GlanceThe drug that sparked a one-day four-bagger is still on track with the FDA.
Sep 24, 2007 by Brian LawlerEncysive Hears the Voice of ReasonTo please the FDA, Encysive returns Thelin to clinical trials.
Sep 24, 2007 by Brian LawlerAn Array of Good NewsThe small pharmaceutical firm signs another big deal.
Sep 20, 2007 by Brian LawlerDiscovering PharmacopeiaPharmacopeia presents at an investors' conference.
Sep 20, 2007 by Brian LawlerHansen Medical Enters Numbers GameShould investors jump in or wait a bit on this maker of a robotic catheter system?
Sep 20, 2007 by Brian LawlerAllergan's Overactive AcquisitionIt acquires the rights to market a new drug.
Sep 19, 2007 by Brian LawlerMillennium Sees SuccessCancer drug shows exceptional promise as it moves toward FDA review.
Sep 18, 2007 by Brian LawlerDirect Your Attention to DURECTPromising drug test results make this a company to watch.
Sep 14, 2007 by Brian Lawler"Dear Doctor" Letter Spells Trouble for CephalonThe potential for harm reduces the uses of painkiller Fentora.
Sep 14, 2007 by Brian LawlerIs Flamel Catching On?A deal with Wyeth is announced, but the financials remain secret.
Sep 13, 2007 by Brian LawlerIs Exelixis Selling Itself Short?It makes sense for the drugmaker to sell millions more shares right now.
Sep 13, 2007 by Brian LawlerImClone Expanding on ErbituxPositive results in cancer study continue ImClone's turnaround.
Sep 13, 2007 by Brian LawlerDon't Bet on the Dendreon LawsuitProvenge supporters weigh in on an FDA decision.
Sep 11, 2007 by Brian LawlerLooking Forward at PfizerThe future will bring generic competition for Lipitor's lucrative base of customers.
